Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy.
Journal Article (Journal Article)
Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson's disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the anti-inflammatory effects that are associated with β2AR activation, this two-pronged attack holds promise for PD treatment and the development of new therapeutic approaches for this disease.
Full Text
Duke Authors
Cited Authors
- Abdelmotilib, H; West, AB
Published Date
- October 19, 2017
Published In
Volume / Issue
- 9 / 1
Start / End Page
- 88 -
PubMed ID
- 29052536
Pubmed Central ID
- PMC5649055
Electronic International Standard Serial Number (EISSN)
- 1756-994X
Digital Object Identifier (DOI)
- 10.1186/s13073-017-0483-4
Language
- eng
Conference Location
- England